Letermovir, an anti-cytomegalovirus (CMV) drug, is recommended as a prophylactic agent in patients at risk of CMV infection/reactivation after allogeneic hematopoietic stem cell transplant. We report the curative and pre-emptive use of letermovir in two heart transplant recipients. In one patient with ganciclovir-resistant CMV, letermovir was successfully used to treat CMV colitis. In the second patient, letermovir was used as pre-emptive therapy for CMV reactivation, but did not prevent CMV esophagitis. In both cases, letermovir was successful for secondary prophylaxis. Curative use of letermovir may be considered if resistance or major adverse effect of other antivirals therapy is suspected.

中文翻译：

---

莱特莫韦用于治疗两名心脏移植受者的复杂巨细胞病毒再激活。

莱特莫韦是一种抗巨细胞病毒 (CMV) 药物，被推荐作为异基因造血干细胞移植后有 CMV 感染/再激活风险的患者的预防药物。我们报告了莱特莫韦在两名心脏移植受者中的治疗性和预防性使用。在一名更昔洛韦耐药 CMV 患者中，莱特莫韦成功用于治疗 CMV 结肠炎。在第二名患者中，莱特莫韦被用作 CMV 再激活的先发制人疗法，但并未预防 CMV 食管炎。在这两种情况下，莱特莫韦都成功用于二级预防。如果怀疑其他抗病毒治疗有耐药性或主要不良反应，可考虑使用莱特莫韦进行治疗。